CRISPR Therapeutics (NASDAQ:CRSP) Stock, Quote.Headers.trade-ideas

CRISPR Therapeutics

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

Dexcom G6 on body

Long Ideas

News

Markets

Media

Trading Ideas

COST

CRSP

DLTR

DXCM

The &#34;Mad Money&#34; host says Dexcom had &#34;a real bad miss... they still really haven&#39;t fully explained why that is.&#34;

Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom

cathie-wood-bz-ark

Equities

ARKG

ARKK

ARKW

COIN

DKNG

NVDA

PATH

PLTR

ROKU

SHOP

TSLA

TWST

In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company&#39;s flagship fund, ARK Innovation ETF, despite its recent underperformance.

Cathie Wood Touts Palantir, Coinbase And Roku As ARK&#39;s Flagship Fund Shifts Focus From Mag 6 Amid &#39;Whiff&#39; Of Lower Interest Rates

Cathie Wood Ark Photo courtesy Benzinga YouTube and Unsplash

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ETFs

$BTC

ARKF

MRNA

PINS

On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), despite Bitcoin (CRYPTO: BTC) reaching new 

Cathie Wood&#39;s Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz

CRISPR Therapeutics AG

Management

AMKR

Amkor Says James Kim Will Be Stepping Down As Executive Chairman And Retiring From Company Effective October 31, 2024; Susan Kim, Executive Vice Chairman, To Become Chairman Of Board At That Time

ALGS

Aligos Therapeutics Plans To Share Topline Results From Phase 2a HERALD Study Of ALG-055009 In Metabolic-dysfunction Associated Steatohepatitis Subjects

<p>During the last three months, 4 analysts shared their evaluations of TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $38.0, a high estimate of $49.00, and a low estimate of $20.00. Observing a 4.83% increase, the current average has risen from the previous average price target of $36.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726693292_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of TG Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TG Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TG Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of TG Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of TG Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TGTX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on TG Therapeutics analyst ratings.</strong></a></p>
<h2>All You Need to Know About TG Therapeutics</h2>
<p>TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.</p>
<h3>TG Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, TG Therapeutics showcased positive performance, achieving a revenue growth rate of <strong>357.05%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> TG Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>9.36%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> TG Therapeutics's ROE excels beyond industry benchmarks, reaching <strong>4.07%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> TG Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.78%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.63</strong>, caution is advised due to increased financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

TGTX

Evaluating TG Therapeutics: Insights From 4 Financial Analysts

<p>In the preceding three months, 6 analysts have released ratings for Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $50.17, a high estimate of $78.00, and a low estimate of $35.00. This upward trend is apparent, with the current average reflecting a 34.4% increase from the previous average price target of $37.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726693276_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Corcept Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corcept Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corcept Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Corcept Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Corcept Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CORT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Corcept Therapeutics analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Corcept Therapeutics</h2>
<p>Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.</p>
<h3>Unraveling the Financial Story of Corcept Therapeutics</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Corcept Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>39.15%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Corcept Therapeutics's net margin excels beyond industry benchmarks, reaching <strong>21.44%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Corcept Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>6.14%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Corcept Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>5.13%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Corcept Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.01</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CORT

Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics

<p>21 analysts have expressed a variety of opinions on PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $78.62, a high estimate of $95.00, and a low estimate of $69.00. This current average reflects an increase of 3.65% from the previous average price target of $75.85. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726693235_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of PayPal Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kazuya Nishimura</td>
<td>Daiwa Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$72.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Anthony Butler</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$83.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Harshita Rawat</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Gus Gala</td>
<td>Monness, Crespi, Hardt</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Anthony Butler</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$71.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>David Togut</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$69.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PayPal Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of PayPal Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of PayPal Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into PayPal Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PYPL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on PayPal Holdings analyst ratings.</strong></a></p>
<h2>Get to Know PayPal Holdings Better</h2>
<p>PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 426 million active accounts at the end of 2023. The company also owns Venmo, a person-to-person payment platform.</p>
<h3>PayPal Holdings: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> PayPal Holdings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>8.21%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>14.31%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> PayPal Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>5.46%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> PayPal Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.35%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.47</strong>, PayPal Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PYPL

Key Takeaways From PayPal Holdings Analyst Ratings

<p>Ratings for Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $91.8, a high estimate of $104.00, and a low estimate of $80.00. Observing a downward trend, the current average is 3.2% lower than the prior average price target of $94.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726693214_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Wyndham Hotels &amp; Resorts by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$104.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$91.50</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Announces</td>
<td>Neutral</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Wyndham Hotels &amp; Resorts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Wyndham Hotels &amp; Resorts compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Wyndham Hotels &amp; Resorts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Wyndham Hotels &amp; Resorts's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Wyndham Hotels &amp; Resorts analyst ratings.</strong></a></p>
<h2>Get to Know Wyndham Hotels &amp; Resorts Better</h2>
<p>As of Dec. 31, 2023, Wyndham Hotels &amp; Resorts operates 872,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 19% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 57% of total rooms.</p>
<h3>A Deep Dive into Wyndham Hotels &amp; Resorts's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Wyndham Hotels &amp; Resorts displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>1.38%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Wyndham Hotels &amp; Resorts's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>23.43%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Wyndham Hotels &amp; Resorts's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>13.26%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Wyndham Hotels &amp; Resorts's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.09%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>3.9</strong>, Wyndham Hotels &amp; Resorts faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 5 Analyst Recommendations For Wyndham Hotels & Resorts

<p>The dividend will be payable on October 31, 2024, to stockholders of record at the close of business on October 23, 2024.</p>


Dividends

Argan Boosts Quarterly Cash Dividend By 25% From $0.30 To $0.375 Per Share

<p><strong>Steelcase Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) shares are falling after the company reported its second-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/09/g40927742/steelcase-reports-second-quarter-fiscal-2025-results">details from the report. </a></p>
<p><strong>The Details:</strong> Steelcase reported quarterly earnings of 39 cents per share, which beat the analyst consensus estimate of 37 cents. Quarterly revenue of $855.8 million missed the analyst consensus estimate of $864.1 million by 0.96%. </p>
<p>The company saw growth in the Americas, driven by higher volume from large corporate, education and government customers, while International business declined, primarily driven by continued weakness in China.</p>
<p>&#8220;Our business continued to improve this quarter as our adjusted earnings grew 26% and we drove 3% order growth in the Americas,&#8221; said <strong>Sara Armbruster</strong>, president and CEO. &#8220;Our education business had especially strong results this quarter, which reflected the benefits of our strategy to diversify the customers and markets we serve.</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/news/large-cap/24/09/40910569/nvidia-salesforce-announce-strategic-ai-collaboration-what-to-know"><strong>NVIDIA, Salesforce Announce Strategic AI Collaboration: What To Know</strong></a></p>
<p><strong>Outlook:</strong> Steelcase sees third-quarter revenue in a range of $785 million to $810 million and adjusted earnings of between 21 cents and 25 cents per share.  </p>
<p><strong>SCS Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Steelcase shares are down 10.21% after-hours at $12.67 at the time of publication Wednesday. </p>
<p><strong>Read Also:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40904271/whats-going-on-with-amazon-stock"><strong>What&#8217;s Going On With Amazon Stock?</strong></a></li>
</ul>
<p><em>Photo: Oleg Gamulinskii from Pixabay</em></p>


Earnings

Guidance

After-Hours Center

Movers

Steelcase Stock Falls After Q2 Revenue Miss: Details

<p>Wall Street reacted with unease to Federal Reserve Chair <strong>Jerome Powell</strong>&#8216;s remarks following a landmark decision to cut the federal funds rate by 50 basis points, bringing it down to a target range <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down">of 4.75% to 5%. </a></p>
<p>The Federal Reserve&#8217;s highly anticipated dot plot, which outlines each policymaker&#8217;s rate path preference, indicated that policymakers <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">anticipate further easing ahead</a>. The dot plot signaled that the Fed is likely to cut rates by a quarter percentage point at each of the next two decisions. Looking further ahead, it suggests an additional rate reduction of at least another percentage point in 2025.</p>
<p>Despite the initial market euphoria following the 50-basis-point rate cut, Powell&#8217;s cautious remarks on the future rate path have injected uncertainty into the markets.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">Interest Rates In Free-Fall &#8211; What It Means For Mortgages, Credit Cards And Your Wallet As The Federal Reserve Springs Into Action For First Time In 4 Years</a></strong></p>
<h3 class="wp-block-heading">Market Response To Rate Cut, Powell&#8217;s Remarks</h3>
<p>Initially, the S&amp;P 500, tracked by the <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), surged to record highs. Gold prices, represented by the <strong>SPDR Gold Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), also hit all-time highs as the U.S. dollar weakened.</p>
<p>Interest-rate sensitive stocks were the largest gainers between 2 p.m. and 2:35 p.m. ET, with small caps outperforming large-cap counterparts.</p>
<p>Yet, Powell&#8217;s cautionary comments during the press conference caused a reversal in market sentiment.</p>
<p>Here&#8217;s how major asset classes closed on the Fed&#8217;s decision day:</p>
<ul>
<li>The U.S. dollar, which many believed would plummet in a 50-basis-point cut scenario, instead recouped its losses and rallied to weekly highs. The Invesco <strong>DB USD Index Bullish Fund ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) closed 0.1% higher.</li>
<li>U.S. large-cap indices all ended the day in the red, paring back gains made immediately after the rate decision. The S&amp;P 500 finished 0.3% lower, while the Nasdaq 100, tracked by the <strong>Invesco QQQ Trust</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), declined by 0.4%.</li>
<li>Small caps managed to close unchanged for the day, but they still gave back all their post-rate-cut gains.</li>
<li>Sector-wise, the <strong>Energy Select Sector SPDR Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) was the only sector to close in positive territory, up 0.2%. </li>
<li>The worst performer was the <strong>Technology Select Sector SPDR Fund </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), which fell 1%.</li>
<li>Gold dropped 0.4% to $2,555 per ounce, hitting levels last seen on Thursday of the previous week.</li>
<li>Silver and oil also saw robust declines, closing 2.1% and 1.2% lower, respectively.</li>
<li><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell 1.1% to $59,717.</li>
</ul>
<h3 class="wp-block-heading">Powell&#8217;s Caution Stirs Investor Uncertainty</h3>
<p>While defending the 50-basis-point rate cut, Powell tempered market enthusiasm, emphasizing that such a cut should not be seen as a new norm. His key statements on Wednesday included:</p>
<ul>
<li>&#8220;No one should look at today and think this is the new pace.&#8221;</li>
<li>&#8220;We can go quicker or slower, or pause, on rate cuts if it is appropriate.&#8221;</li>
<li>&#8220;There is nothing in our projections that suggest we are in a rush.&#8221;</li>
<li>&#8220;If the economy remains solid and inflation persists, we can dial back policy restraint more slowly.&#8221;</li>
</ul>
<p>These comments signaled a more cautious approach to future rate cuts, disappointing investors who had hoped for a more aggressive easing cycle.</p>
<h3 class="wp-block-heading">Economist Insights</h3>
<ul>
<li><strong>Jeffrey Roach, </strong>LPL Financial<strong>:</strong> &#8220;We learned from today's Summary of Economic Projections (SEP) that the Fed is interested in getting to a neutral fed funds rate as quickly as possible.&#8221;</li>
<li><strong>John Lynch, </strong>Comerica Wealth Management: &#8220;The Fed was more aggressive than I expected, since 50 basis point cuts are historically associated with crises. I don't consider 2% GDP, 4.2% unemployment rate, and 15% profit growth forecasts for 2025 as a crisis.&#8221;</li>
<li><strong>Bill Adams, </strong>Comerica Bank<strong>:</strong> &#8220;With the Fed pivoting, interest rates will be substantially lower over the next six to twelve months. That is very welcome news for credit-sensitive sectors of the economy like housing, manufacturing, and retailers of cars and other big-ticket consumer products.&#8221;</li>
<li><strong>Chris Zaccarelli, </strong>Independent Advisor Alliance<strong>:</strong> &#8220;Lowering interest rates now should allow the market to hit all-time highs again by the end of this year, and more gains for next year.&#8221;</li>
</ul>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/09/40923390/20-s-p-500-stocks-that-move-the-most-when-the-fed-starts-cutting-interest-rates">20 S&amp;P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates</a></strong></li>
</ul>
<p><em>Photo courtesy of the Federal Reserve. </em></p>


Analyst Color

Large Cap

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Tech

PowerShares DB US Dollar Index Bullish Fund

Powell's Hawkish Tone Tempers Market Excitement After Historic 50-Basis-Point Interest Rate Cut, Economist Sees 'Welcome News For Credit-Sensitive Sectors'

<p>Cannabinoid-focused biopharmaceutical company <strong>C3 Pharmaceuticals, Inc.</strong> announced Wednesday that it has executed a tailored share subscription agreement with <strong>GEM Global Yield LLC SCS</strong> and is planning on listing on the Canadian Securities Exchange.</p>
<p>The California company said it has a commitment of CAD$135 million ($99.3 million) from GGY. The money will expand manufacturing operations and introduce<strong> </strong>Idrasil,<strong> </strong>the company's cannabis-based tablet, to the U.S. and international markets, according to C3. </p>
<p>The tablet is aimed at helping patients manage a variety of conditions, such as chronic pain, ADD, Alzheimer&#8217;s, cancer, sleep disorders, mental health issues and withdrawal from opioid addiction, while remaining sober and lucid.</p>
<p>&#8220;Idrasil is expected to be a highly disruptive medical advancement in recent pharmaceutical history,&#8221; CEO <strong>Steele Smith III</strong> said in Wednesday&#8217;s press release. "This is why there have been legal and bureaucratic obstacles to bringing it to market and securing insurance approvals."</p>
<p><strong>Read Also:</strong> <strong><a href="https://www.benzinga.com/markets/cannabis/24/04/38211713/cannabis-ceo-to-sec-attorney-eat-s">Cannabis CEO To SEC Attorney: &#8216;Eat S&#8212;&#8216;</a></strong></p>
<p>Idrasil is in the center of a long-running lawsuit filed by the Securities and Exchange Commission against C3 International, Inc., co-founded by Smith and his wife Theresa. </p>
<p>On Monday, C3 International and the Smiths filed an appeal with the 9th U.S. Circuit Court of Appeals of a July 17 order by U.S. District Judge <strong>Christina Snyder</strong> that granted a default judgment barring the defendants from breaching securities laws and imposed $1,914,017 in disgorgement, $447,859 in prejudgment interest and $621,459 in civil penalties. </p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</em></strong></li>
</ul>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cannabis/24/08/40133840/cannabis-pharmaceuticals-company-with-ties-to-groundbreaking-medical-developments-pursues-cannab">Cannabis Pharmaceuticals: Company With Ties To Groundbreaking Medical Developments Pursues Cannabinoid-Based Medicines</a></strong></li>
</ul>
<p><em>Photo via Shutterstock. </em></p>


Cannabis

Legal

C3 Pharmaceuticals Announces IPO Plans On Canadian Exchange, Funding For Cannabis Tablet As SEC Battle Continues

<p>Shares of low-float micro-cap stock <strong>Exicure Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) are rocketing higher in Wednesday&#8217;s after-hours session after the company announced that it received an extension from the <a href="https://www.benzinga.com/pressreleases/24/09/b40927658/exicure-inc-receives-extension-from-nasdaq-hearings-panel">Nasdaq Hearings Panel</a>.</p>
<p><strong>What Happened:</strong> After the market close, Exicure announced that it was granted an extension for continued listing on the Nasdaq exchange. The early-stage biotechnology company must now show compliance with all applicable criteria for continued listing on the Nasdaq by Nov. 14.</p>
<p>Exicure <a href="https://www.benzinga.com/news/24/09/40884303/whats-going-on-with-exicure-shares-monday">announced</a> at the end of last week that it regained compliance with Nasdaq&#8217;s minimum bid price requirement and exchanged approximately&nbsp;$1 million&nbsp;of debt for equity at a conversion price of&nbsp;$3&nbsp;per share.</p>
<p>The company on Wednesday said it&#8217;s diligently working to satisfy the remaining terms of the Nasdaq Panel&#8217;s requests in order to ensure Exicure&#8217;s continued listing.</p>
<p><strong>Related Link: <a href="https://www.benzinga.com/markets/penny-stocks/24/09/40898685/reneo-pharmaceuticals-and-2-other-stocks-under-5-executives-are-buying">Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying</a></strong></p>
<p>Exicure shares have more than doubled in extended trading and are now hitting new 52-week highs. Exicure is considered a low-float stock with just 1.118 million shares available for public trading, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. </p>
<p>The company also had a market cap of less than $4 million as of Wednesday&#8217;s close. </p>
<p>Low-float, micro-cap stocks can be extremely volatile, which may help explain some of Wednesday&#8217;s outsized move.</p>
<p><strong>XCUR Price Action:</strong> Exicure shares were up 206.55% in after-hours, trading at $7.10 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: Shutterstock.</em></p>
<p><strong>Read Next:</strong> </p>
<ul>
<li><a href="https://www.benzinga.com/fintech/24/09/40928342/what-happened-with-sofi-stock-today"><strong>What Happened With SoFi Stock Today?</strong></a></li>
</ul>


Biotech

XCUR

Exicure Stock Is Soaring After The Bell: What's Driving The Action?

<p><strong>Children's Place's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NYSE">PLCE</a>) short percent of float has risen 26.48% since its last report. The company recently reported that it has <strong>2.82 million shares sold short</strong>, which is 53.78% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 9.27 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Children's Place Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726692321_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Children's Place has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Children's Place's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Children's Place's peer group average for short interest as a percentage of float is 12.24%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

PLCE

(PLCE) - Analyzing Children's Place's Short Interest

<p><strong>Taiwan Semiconductor Manufacturing Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) stock lost 4% in the last 30 days. Last month saw volatility as <strong>Nvidia Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) released its quarterly print and more.</p>
<p>The <strong>VanEck Semiconductor ETF </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and <strong>iShares Semiconductor ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>), representing the semiconductor industry, have lost ~7% in the last 30 days. Now, let&#8217;s run down the events for Taiwan Semiconductor since Nvidia released its quarterly print.</p>
<p>On August 28, Nvidia reported <a target="_blank" href="https://www.benzinga.com/trading-ideas/24/08/40652614/nvidia-shatters-revenue-records-with-a-staggering-30-billion-quarter-yet-sees-stock-prices-slide-se" rel="noreferrer noopener">second-quarter topline</a> growth of 122% to $30.04 billion, quashing the&nbsp;analyst consensus of $28.68 billion.</p>
<p><figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18135430/newplot-14.png" alt="" class="wp-image-554700" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18135430/newplot-14.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18135430/newplot-14-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure></p>
<p><strong><em>Also Read:</em></strong><em> <a target="_blank" href="https://www.benzinga.com/news/24/09/40897994/whats-going-on-with-intel-stock-on-tuesday" rel="noreferrer noopener">Intel Looks To Restructure Foundry Business, Bags Major US Deal and Government Grants</a></em></p>
<p>The company projected third-quarter revenue of $31.85 billion—$33.15 billion, versus the consensus of $31.77 billion.</p>
<p>Still, the stock dropped by <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40614118/nvidia-leads-semiconductor-stocks-lower-following-q2-earnings-what-investors-need-to-know" rel="noreferrer noopener">6% in after-hours trading</a>, sending semiconductor stocks, including Taiwan Semiconductor, <strong>Advanced Micro Devices, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), <strong>and Super Micro Computer, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), down as the print failed to impress the Street.</p>
<p>The semiconductor sector selloff <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40684198/nvidia-tsmc-lead-chip-stocks-lower-in-premarket-whats-going-on" rel="noreferrer noopener">continued in September</a>, with U.S.-China geopolitical tensions intensifying due to the Western counterpart&#8217;s artificial intelligence technology embargo on the Asian counterpart.</p>
<p>Meanwhile, Taiwan Semiconductor remained invested in solidifying its moat by <a target="_blank" href="https://www.benzinga.com/news/24/09/40686890/apple-nvidia-key-supplier-tsmc-leads-taiwanese-chip-giants-to-localize-neon-gas-production-by-2025" rel="noreferrer noopener">localizing neon gas production</a>, a key chipmaking material disrupted by the Ukraine war, and fast-tracking the development of silicon photonics to address the energy and data transmission speeds <a target="_blank" href="https://www.benzinga.com/news/24/09/40687807/whats-going-on-with-taiwan-semiconductor-stock-on-tuesday" rel="noreferrer noopener">needed by AI computing</a>.</p>
<p>Taiwan Semiconductor <a target="_blank" href="https://www.benzinga.com/news/24/09/40711613/taiwan-semiconductor-bets-on-ai-growth-surge-samsung-joins-ai-optimism-in-trade-show" rel="noreferrer noopener">projected a 50%</a> growth in AI accelerators at the Semicon Taiwan industry forum in Taipei despite concerns over the sustainability of the AI frenzy, which is sending jitters across the market. <strong>Broadcom Inc&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) quarterly print and guidance did little to contain <a target="_blank" href="https://www.benzinga.com/news/24/09/40754938/semiconductor-etfs-take-a-beating-dragged-lower-by-nvidia-amd-and-broadcom-stocks" rel="noreferrer noopener">the semiconductor selloff</a>.</p>
<p>On the brighter side, reports indicated that the contract chipmaker&#8217;s production yield at the Arizona facility is at par with<a target="_blank" href="https://www.benzinga.com/government/24/09/40773084/taiwan-semiconductors-us-plant-matches-taiwan-production-yields-stock-gains" rel="noreferrer noopener"> its Taiwan facilities</a>.</p>
<p>Taiwan Semiconductor reported <a target="_blank" href="https://www.benzinga.com/news/24/09/40790997/taiwan-semiconductors-strong-august-sales-hint-at-big-gains-ahead-ai-and-iphone-demand-fuel-optimism" rel="noreferrer noopener">33% topline growth</a> in&nbsp;August 2024, testimony to the smartphone market recovery and continued demand for&nbsp;Nvidia AI chips. Analysts expect third-quarter revenue growth of 37%.</p>
<p>Some of Taiwan Semiconductors key September wins included a <strong>Alphabet Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google smartphone deal&nbsp;involving <a target="_blank" href="https://www.benzinga.com/news/24/09/40833611/google-picks-taiwan-semiconductor-for-pixel-chips-samsung-loses-key-deal-report" rel="noreferrer noopener">Pixel 10 and Pixel 11 chips</a> and <strong>Apple Inc&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) A16 chip at <a target="_blank" href="https://www.benzinga.com/news/24/09/40920976/taiwan-semiconductor-begins-production-of-apple-a16-smartphone-chips-at-arizona-facility-report" rel="noreferrer noopener">its Arizona Fab</a>.</p>
<p>Taiwan Semiconductor is up over 90% in the last 12 months as it led the&nbsp;global foundry market, commanding a 62% share in the <a target="_blank" href="https://www.benzinga.com/news/24/09/40711613/taiwan-semiconductor-bets-on-ai-growth-surge-samsung-joins-ai-optimism-in-trade-show" rel="noreferrer noopener">second quarter of 2024</a>.</p>
<p><strong>Price Action: </strong>TSM stock closed at $167.28 on Wednesday.</p>
<p><em>Image via Shutterstock</em></p>


AAPL

AVGO

GOOG

GOOGL

SMCI

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

What has Taiwan Semiconductor Stock Done Since Nvidia Earnings?

<p><strong>Eastern Bankshares's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBC#NYSE">EBC</a>) short percent of float has fallen 7.49% since its last report. The company recently reported that it has <strong>3.43 million shares sold short</strong>, which is 1.73% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.79 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Eastern Bankshares Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726692316_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Eastern Bankshares has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Eastern Bankshares's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eastern Bankshares's peer group average for short interest as a percentage of float is 4.88%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into Eastern Bankshares's Recent Short Interest

<p><strong>United States Steel's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) short percent of float has risen 7.42% since its last report. The company recently reported that it has <strong>19.70 million shares sold short</strong>, which is 8.83% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 5.62 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>United States Steel Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726692310_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for United States Steel has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing United States Steel's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, United States Steel's peer group average for short interest as a percentage of float is 4.81%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


(X) - Analyzing United States Steel's Short Interest

<p>Financial giants have made a conspicuous bullish move on Dollar Gen. Our analysis of options history for Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 44% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $588,385, and 4 were calls, valued at $391,647.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $105.0 for Dollar Gen over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Dollar Gen's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Dollar Gen's whale activity within a strike price range from $70.0 to $105.0 in the last 30 days. </p>
<h3>Dollar Gen Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726691582_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.75</td>
<td>$11.7</td>
<td>$11.75</td>
<td>$80.00</td>
<td>$345.4K</td>
<td>588</td>
<td style="text-align: right;">385</td>
</tr>
<tr>
<td>DG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$14.45</td>
<td>$13.05</td>
<td>$13.05</td>
<td>$95.00</td>
<td>$261.0K</td>
<td>1.4K</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.35</td>
<td>$11.75</td>
<td>$11.75</td>
<td>$80.00</td>
<td>$105.7K</td>
<td>588</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>DG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.15</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$105.00</td>
<td>$78.4K</td>
<td>6</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.8</td>
<td>$8.75</td>
<td>$8.75</td>
<td>$85.00</td>
<td>$68.2K</td>
<td>1.6K</td>
<td style="text-align: right;">78</td>
</tr>
</tbody>
</table>
</p>
<h3>About Dollar Gen</h3>
<p>With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.</p>
<p>After a thorough review of the options trading surrounding Dollar Gen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Dollar Gen's Current Market Status</h3>
<ul>
<li>With a volume of 3,489,659, the price of DG is up 0.99% at $86.86. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What The Experts Say On Dollar Gen</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $112.4.</p>
<ul>
<li>An analyst from Evercore ISI Group persists with their In-Line rating on Dollar Gen, maintaining a target price of $100. </li>
<li>Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Dollar Gen with a target price of $130. </li>
<li>Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Dollar Gen with a target price of $122. </li>
<li>Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Dollar Gen with a target price of $120. </li>
<li>An analyst from BMO Capital has decided to maintain their Market Perform rating on Dollar Gen, which currently sits at a price target of $90. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Dollar Gen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Unpacking the Latest Options Trading Trends in Dollar Gen

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Coherent</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with COHR, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 16 options trades for <strong>Coherent</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 68% bullish and 31%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $49,980, and 15, calls, for a total amount of $1,125,050.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $110.0 for Coherent during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Coherent's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Coherent's whale trades within a strike price range from $60.0 to $110.0 in the last 30 days. </p>
<h3>Coherent Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726691577_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$26.5</td>
<td>$25.1</td>
<td>$26.5</td>
<td>$60.00</td>
<td>$265.0K</td>
<td>103</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.6</td>
<td>$2.9</td>
<td>$3.5</td>
<td>$110.00</td>
<td>$263.7K</td>
<td>93</td>
<td style="text-align: right;">754</td>
</tr>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$4.4</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$80.00</td>
<td>$82.0K</td>
<td>4.6K</td>
<td style="text-align: right;">207</td>
</tr>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.6</td>
<td>$100.00</td>
<td>$74.9K</td>
<td>874</td>
<td style="text-align: right;">224</td>
</tr>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$10.1</td>
<td>$10.0</td>
<td>$10.1</td>
<td>$75.00</td>
<td>$50.5K</td>
<td>788</td>
<td style="text-align: right;">101</td>
</tr>
</tbody>
</table>
</p>
<h3>About Coherent</h3>
<p>Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.</p>
<p>Following our analysis of the options activities associated with Coherent, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Coherent</h3>
<ul>
<li>With a volume of 4,787,861, the price of COHR is up 4.16% at $81.16. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 47 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Coherent options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


COHR

Coherent Unusual Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards Medical Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MPW usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Medical Properties Trust. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 72% leaning bullish and 27% bearish. Among these notable options, 7 are puts, totaling $348,980, and 4 are calls, amounting to $257,760.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $10.0 for Medical Properties Trust during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Medical Properties Trust's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Medical Properties Trust's whale activity within a strike price range from $5.0 to $10.0 in the last 30 days. </p>
<h3>Medical Properties Trust Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726691572_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MPW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$0.52</td>
<td>$0.5</td>
<td>$0.52</td>
<td>$10.00</td>
<td>$168.7K</td>
<td>14.3K</td>
<td>3.2K</td>
</tr>
<tr>
<td>MPW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.23</td>
<td>$2.21</td>
<td>$2.21</td>
<td>$7.00</td>
<td>$99.5K</td>
<td>4.4K</td>
<td>500</td>
</tr>
<tr>
<td>MPW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.22</td>
<td>$1.18</td>
<td>$1.18</td>
<td>$6.00</td>
<td>$59.0K</td>
<td>399</td>
<td>4</td>
</tr>
<tr>
<td>MPW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.17</td>
<td>$1.16</td>
<td>$1.16</td>
<td>$7.00</td>
<td>$52.2K</td>
<td>182</td>
<td>702</td>
</tr>
<tr>
<td>MPW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.63</td>
<td>$0.58</td>
<td>$0.58</td>
<td>$5.50</td>
<td>$43.4K</td>
<td>8.6K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Medical Properties Trust</h3>
<p>Medical Properties Trust Inc is a healthcare facility REIT. The company operates one segment, which owns and leases healthcare facilities. The vast majority of Medical's revenue is generated in the United States, followed by Germany and the United Kingdom. It provides financing for a variety of facilities that require funds for acquisitions, sale-leasebacks, new developments, and expansion projects.</p>
<p>Having examined the options trading patterns of Medical Properties Trust, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Medical Properties Trust Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 17,434,986, with MPW's price down by -4.65%, positioned at $5.95.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 36 days.</li>
</ul>
<h3>Professional Analyst Ratings for Medical Properties Trust</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $6.25.</p>
<ul>
<li>An analyst from Truist Securities persists with their Hold rating on Medical Properties Trust, maintaining a target price of $6. </li>
<li>In a positive move, an analyst from Colliers Securities has upgraded their rating to Buy and adjusted the price target to $6. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Medical Properties Trust with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


A Closer Look at Medical Properties Trust's Options Market Dynamics

MCAG

Mountain Crest Acquisition Corp. V Receives Nasdaq Deficiency Notification

AIG Appoints Keith Walsh Executive Vice President, Chief Financial Officer, Effective Oct. 21

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Globus Medical (GMED – Research Report), Novo Nordis...

Wall Street Analysts Are Bullish on Top Healthcare Picks

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (<span>CAGR</span>) of 30% through 2030. Efficiencies could <a href="https://assets.arkinvest.com/media-8e522a83-1b23-4d58-a202-792712f8d2d3/3ca398a4-8e1d-41f9-9868-0b6002a9d191/ARK-Invest_Big-Ideas-2024_FINAL.pdf">contribute $1.5 trillion</a> to the enterprise value of companies pursuing these technologies.</p>



<p>Over the next five years or so, gene-editing using CRISPR-based processes to target and cure rare diseases and chronic conditions will expand at a 46% CAGR.</p>



<p>Wood seeks out opportunities to generate phenomenal returns by buying representative stocks early and watching them evolve. While that means her returns in the gene-editing field may lag the market indexes for a time, the investing guru has a much longer investment horizon. You should too.</p>



<p>Buying the <a href="https://investorplace.com/2024/07/the-top-3-cathie-wood-stocks-to-buy-now-summer-2024/">best gene-editing stocks</a> shouldn&rsquo;t be thought of as a get-rich-quick scheme. It will take years for the companies using and pursuing these technologies to achieve full valuation. But adding the best gene-editing stocks to your portfolio now gives you the chance to ensure tremendous returns down the road. Here are three stocks to buy today.</p>



<h2>CRISPR Therapeutics (CRSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/crispr-theraputics-crsp-stock-1600-300x169.jpg" alt="the CRISPR Therapeutics (CRSP) logo seen displayed on a smartphone"><div>Source: rafapress / Shutterstock.com</div></div><p>Any discussion of CRISPR-based technology has to begin with <strong>CRISPR Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/crsp-stock-quote/"><strong>CRSP</strong></a></span>), the leading player in the space.</p>



<p>Otherwise known as Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR directs the programmable enzyme Cas9 to <a href="https://investorplace.com/2024/07/the-top-3-cathie-wood-stocks-to-buy-now-summer-2024/">cleave DNA with extreme precision</a> in virtually any organism. CRISPR Therapeutics is using the procedure to develop cutting-edge therapies to target rare diseases.&nbsp;</p>



<p>It is not an overnight success, though after developing its first successful treatment targeting rare blood diseases, it may look that way. CRISPR&rsquo;s Casgevy is for patients with transfusion-dependent beta-thalassemia (<span>TDT</span>) and sickle cell disease (<span>SCD</span>).</p>



<p>TDT is a <a href="https://www.biospace.com/thalassemia-market-size-to-reach-usd-3-0-billion-by-2034-impelled-by-several-novel-medications#:~:text=The%20thalassemia%20market%20size%20reached,3.84%25%20during%202024%2D2034.">$3 billion market opportunity</a> that could grow to $4 billion by 2034. The National Institute of Health says the rare hereditary blood disorder <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429534/">affects approximately 2,000 individuals</a> in the U.S. CRISPR has <a href="https://investorplace.com/2023/08/got-600-here-are-3-no-brainer-stocks-you-absolutely-must-buy/">partnered with the much larger</a> <strong>Vertex Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vrtx-stock-quote/"><strong>VRTX</strong></a></span>) to market Casgevy.</p>



<p>The therapy received Food and Drug Administration approval only in December, and CRISPR has already <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1674416/000095017024055689/crsp-20240508.htm">activated 25 treatment centers</a> globally to treat patients. The drug can only be administered in authorized facilities after first collecting cells from the patient. CRISPR reported that it has begun that process with multiple patients.</p>



<p>Although the biotech will only receive 40% of the revenue Vertex generates from marketing the therapy, look for CRISPR Therapeutics to see sales grow. Especially as it has a robust pipeline, this is one of the best gene-editing stocks to buy.&nbsp;</p>



<h2>Silence Therapeutics (SLN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/lab-300x169.jpg" alt="Scientists in a lab"><div>Source: Matej Kastelic / Shutterstock</div></div><p>Gene silencing is a new treatment technique that uses the body&rsquo;s <a href="https://silence-therapeutics.com/patients/gene-silencing-explained/gene-silencing-the-basics/default.aspx">natural suppression of gene expression</a>, or &ldquo;silencing&rdquo; it, to treat diseases. While gene therapy is more widely known, silencing has distinct advantages. It does not introduce new genes into the body but rather uses already -existing biological processes to treat a disease.</p>



<p><strong>Silence Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sln-stock-quote/"><strong>SLN</strong></a></span>) is a leader in RNA silencing or interference. Because our bodies already naturally perform the task of defending against viruses or controlling gene activity, silencing is a safer and reversible process should there be an adverse reaction.</p>



<p>Silence Therapeutics recently reported that its lead drug candidate, zerlasiran (SLN360), <a href="https://investorplace.com/2024/07/morgan-stanley-predicts-triple-digit-rally-for-these-3-stocks/">achieved positive results</a> during Phase 2 clinical trials. The therapy targets patients with a high risk of atherosclerotic cardiovascular disease.</p>



<p>With the stock market crashing, Silence Therapeutics stock is tumbling into negative territory for the year but is still up over 150% over the last 12 months. Investors should take advantage of the discount the market is offering to buy this top gene-editing stock.</p>



<h2>Alnylam Pharmaceuticals (ALNY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/alny1600-300x169.png" alt="Illustrative Editorial of Alnylam Pharmaceuticals Inc website homepage. Alnylam Pharmaceuticals Inc logo visible on display screen. ALNY stock"><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Alnylam Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/alny-stock-quote/"><strong>ALNY</strong></a></span>) is another biotech pursuing RNA interference (RNAi) therapies. Its vutrisiran is a treatment for a rare, aggressive heart condition called transthyretin amyloid cardiomyopathy (ATTR&#8209;CM). In late-stage trials, vutrisiran recently reported positive Phase 3 results.</p>



<p>Marketed as Amvuttra, vutrisiran was shown to cut the risk of death from ATTR-CM by more than a third. It targets a protein made in the liver called prealbumin and, using RNAi, seeks to neutralize the gene&rsquo;s expression.&nbsp;</p>



<p>CEO Yvonne Greenstreet <a href="https://firstwordpharma.com/story/5869456">called the late-stage results</a> a &ldquo;home run.&rdquo; She believes vutrisiran puts in Alnylam Pharmaceuticals&rsquo; &ldquo;hands a multibillion-dollar opportunity.&rdquo; It means the biotech has a <a href="https://investorplace.com/2024/07/alnylam-stock-is-a-blockbuster-biopharma-in-the-making/">blockbuster in the making</a>.</p>



<p>Alnylam just reported strong second-quarter results with Amvuttra sales driving 34% year-over-year revenue growth to $410 million. Amvuttra <a href="https://alnylampharmaceuticalsinc.gcs-web.com/static-files/52c713b4-aead-430c-b2ec-f92b47d4783b">represented 56% of total sales</a>, or $230 million. If vutrisiran gets FDA approval, investors could see revenue rocket to new heights, making it one of the best gene-editing stocks to buy.</p>



<p><em>On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or<br>indirectly) any positions in the securities mentioned in this article</em>.</p>
<div><p>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/the-3-best-gene-editing-stocks-to-buy-in-august-2024/">The 3 Best Gene Editing Stocks to Buy in August 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 3 Best Gene Editing Stocks to Buy in August 2024

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Crispr Therapeutics AG (CRSP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkc...

Crispr Therapeutics AG: Strategic Progress and Strong Financials Bolstering a Buy Rating

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>With the market struggling amid rising recession fears, now may be the ideal time to consider <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. First, the sector itself is a financially lucrative one. Last year, the ecosystem <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">reached a valuation of $1.55 trillion</a>. Between 2024 to 2030, the segment could expand at a compound annual growth rate (CAGR) of 13.96% to $3.88 trillion.</p>



<p>Along this line of thinking, the current market fallout makes biotech stocks all the more intriguing. No matter what, society will always push for solutions that address the human condition. From cancer to autoimmune diseases and other conditions and ailments, the search for effective treatments is a perpetual one. Not only that, a healthy society is an economically productive and efficient one.</p>



<p>Therefore, it&rsquo;s no surprise that government support and incentives underline various biotech-related initiatives. It&rsquo;s in all of our best interests to promote overall wellness. And in that sense, the narrative is recession resistant. With that in mind, below are biotech stocks you can now pick up on a relative discount.</p>



<h2>Crispr Therapeutics (CRSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/crispr_crsp1600-300x169.jpg" alt="CRISPR (CRSP) logo within a DNA sequence"><div>Source: Catalin Rusnac/ShutterStock.com</div></div><p>One of the most groundbreaking innovators among biotech stocks, <strong>Crispr Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crsp-stock-quote/"><strong>CRSP</strong></a>) specializes in gene-editing therapies. Primarily, the company&rsquo;s CRISPR/Cas9 platform &ndash; a genome-editing technology that allows scientists to precisely alter DNA &ndash; may have the potential to cure various genetic disorders. Crispr aims to do so by essentially fixing faulty genes.</p>



<p>While CRSP stock is certainly enticing, its main challenge is profitability (or lack thereof). In the past year since the second quarter, Crispr posted an average loss per share of 81 cents. Now, in Q4 of last year, it posted earnings per share of $1.10, beating the expected loss of 7 cents. That demonstrates that Crispr has potential &ndash; it just needs to demonstrate this more often.</p>



<p>Right now, it&rsquo;s not the most attractively priced security, trading hands at 14.7x trailing-year sales. In contrast, the biotech sector&rsquo;s <a href="https://fullratio.com/ps-ratio-by-industry">average revenue multiple sits at 6.23x</a>. Still, in the past year, CRSP&rsquo;s average price-to-sales ratio stood at 27.09.</p>



<p>After a potentially rough outing in fiscal 2024, the following year could see <a href="https://finance.yahoo.com/quote/crsp/analysis">sales rise to $332.54 million</a>, with a blistering high-side estimate of $3.31 billion.</p>



<h2>Voyager Therapeutics (VYGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Focused on the development of gene therapies for severe neurological diseases, <strong>Voyager Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vygr-stock-quote/"><strong>VYGR</strong></a>) represents one of the top biotech stocks to consider. Its lead candidate is VY-TAU01, which is an anti-tau antibody program for the treatment of Alzheimer&rsquo;s disease. In its pipeline, it also features a gene therapy that addresses amyotrophic lateral sclerosis or ALS.</p>



<p>As with other biotech stocks, Voyager has trouble with generating consistent profitability. True, in Q4, the company posted EPS of $1.25. This dramatically exceeded the consensus target calling for a loss of 29 cents per share. However, the company has struggled in other quarters to print positive results. That also didn&rsquo;t change with the <a href="https://investorplace.com/earning-results/2024/08/vygr-stock-earnings-voyager-therapeutics-for-q2-of-2024/">latest Q2 results</a>.</p>



<p>At the moment, VYGR stock trades hands at 3.23x sales. While that seems undervalued, it&rsquo;s a deceptive figure since analysts are projecting that by the end of this year, sales may land at $48.51 million. If so, that would imply an 80.6% drop from last year&rsquo;s tally of $250.01 million.</p>



<p>However, because of the demand for treatment solutions for neurological diseases, VYGR stock is worth keeping on your watchlist.</p>



<h2>Sarepta Therapeutics (SRPT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/genetics-dna-flgt-1600-300x169.jpg" alt="a visualization of DNA in a vial. TSHA stock"><div>Source: Connect world / Shutterstock.com</div></div><p>A specialist in the field of precision genetic medicine, <strong>Sarepta Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/"><strong>SRPT</strong></a>) focuses on rare neuromuscular diseases. In particular, its RNA-targeted therapies and gene therapies provide hope for patients suffering from conditions such as Duchenne muscular dystrophy. While SPRT stock has been a strong performer this year, the market fallout has negatively impacted the company&rsquo;s valuation.</p>



<p>Curretnly, SRPT stock trades hands at 9.53x sales. That&rsquo;s a modest discount compared to the prior year&rsquo;s average multiple of 9.57x. Further, it&rsquo;s elevated compared to the industry average. However, it&rsquo;s worth pointing out that in fiscal 2024, analysts <a href="https://finance.yahoo.com/quote/srpt/analysis">project sales to hit $2.02 billion</a>. If so, this figure would represent a 62.6% lift from the prior year&rsquo;s haul of $1.24 billion. In addition, the high-side estimate calls for $2.32 billion.</p>



<p>Assuming a shares outstanding count of 94.52 million, SRPT is currently trading at around 5.73x projected high-side revenue. It&rsquo;s more than possible that Sarepta could hit that target considering that in fiscal 2025, the consensus view for sales calls for $3.27 billion. With so much excitement built into this space, SRPT ranks among the biotech stocks to buy.</p>



<h2>Regenxbio (RGNX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div><p>Another gene-therapy focused enterprise, <strong>Regenxbio</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgnx-stock-quote/"><strong>RGNX</strong></a>) is a clinical-stage biotech that utilizes a proprietary platform called NAV Technology. This platform enables Regenxbio to develop advanced therapeutic candidates for vexing conditions such as wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. It also features solutions for other conditions such as muscular dystrophy.</p>



<p>Coming upon a familiar theme among biotech stocks, Regenxbio has trouble with consistent profitability. In the past year since Q2, the company incurred a loss per share of $1.32. That said, analysts anticipated a loss of $1.34 during the same period. Therefore, the biotech managed to post a modest &ldquo;earnings&rdquo; surprise of 0.92%.</p>



<p>Right now, RGNX stock trades hands at 6.47x sales. That&rsquo;s roughly in line with the industry average. However, it&rsquo;s noticeably lower than the prior year&rsquo;s average multiple of 7.86x. Analysts see modest growth this year. However, in fiscal 2025, sales could soar to $249.2 million, a far cry from last year&rsquo;s print of $90.24 million.</p>



<h2>Blueprint Medicines (BPMC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/nktx_cancerresearch1600-300x169.png" alt="DNA strand and Cancer Cell Oncology Research Concept 3D rendering. LIXT Stock"><div>Source: CI Photos / Shutterstock.com</div></div><p>Another specialist in the field of precision medicine, <strong>Blueprint Medicines</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpmc-stock-quote/"><strong>BPMC</strong></a>) focuses on specific groups of cancers and rare diseases. It&rsquo;s potentially one of the groundbreaking biotech stocks thanks to the underlying targeted approach to cancer treatment. Essentially, Blueprint designs therapeutics based on the specific genetic mutations catalyzing the disease, potentially improving efficacy and reducing complications.</p>



<p>As with other biotech stocks, Blueprint is sporadic in terms of its bottom line. In the past year since Q2, the company posted an average loss per share of 86 cents. In Q1, it managed to deliver EPS of $1.40, far exceeding the expected loss of $1.66. However, investors will eventually want to see more of these positive figures.</p>



<p>Now, BMPC stock is risky, trading hands at 16.06x sales. That&rsquo;s a screaming hot premium. But to be fair, in the prior year, the average multiple stood at 21.41x. The kicker, though, is the fiscal 2024 forecast. Experts believe that revenue could jump to $491.86 million. If so, that would imply a near doubling from last year&rsquo;s print of $249.38 million.</p>



<h2>Precision BioSciences (DTIL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/gene-edit-300x169.png" alt="An image of a scientist holding forceps, taking a piece of a DNA helix"><div>Source: Panuwach/Shutterstock</div></div><p>A biotechnology firm focused on the genome editing, <strong>Precision BioSciences</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtil-stock-quote/"><strong>DTIL</strong></a>) utilizes a proprietary platform called ARCUS to develop therapies for genetic diseases and cancer. Theoretically, this unique platform enables Precision to design highly specified genetic modifications. This process can potentially lead to more effective and safer therapies.</p>



<p>Unlike many other biotech stocks in its class, Precision has started to generate consistent profits. In the second half of 2023, the company incurred an average loss per share of $3.08. However, in the first half of this year, the average EPS stands at almost $3.19. In the past four quarters, the average EPS is 5 cents, yielding an earnings surprise of 139.8%.</p>



<p>Enticingly, shares trade hands at only 0.51x sales. What&rsquo;s more, in the prior year, the market accepted a multiple of 1.1x. Therefore, DTIL stock potentially has room to run. That&rsquo;s exactly what analysts are anticipating, projecting that fiscal 2024 sales may hit $72.47 million. That&rsquo;s up 48.7% from last year&rsquo;s tally of $48.73 million.</p>



<h2>Allogene Therapeutics (ALLO)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/allogene.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/allogene-300x169.jpg" alt="The logo for Allogene Therapeutics Inc (ALLO) is displayed on a building front."></a><p>A clinical-stage immuno-oncology firm, <strong>Allogene Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/allo-stock-quote/"><strong>ALLO</strong></a>) develops and commercializes genetically engineered allogeneic T-cell therapies for the treatment of cancer. Specifically, its platform targets pediatric and adult patients suffering from leukemia. According to its website, one of Allogene&rsquo;s core advantages is its scalable and efficient manufacturing process. This attribute enables potentially lifesaving care at reduced cost, holistically easing the burden of treatment.</p>



<p>Allogene isn&rsquo;t a profitable enterprise so it will require significant patience &ndash; more so than many other biotech stocks. In addition, the company doesn&rsquo;t generate much in terms of revenue. Last year, the company posted only $95,000 on the top line. What&rsquo;s worse, by the end of the current year, analysts believe that sales could dip to $50,000.</p>



<p>So, why bother with ALLO stock? Aside from the groundbreaking treatment potential, covering experts believe that by fiscal 2025, revenue could soar to $4.1 million. Further, the high-side estimate calls for $60.97 million.</p>



<p>Interestingly, assuming a shares outstanding count of 208.78 million, ALLO stock is trading at 8.53x projected high-side 2025 revenue. That&rsquo;s not bad considering the therapeutic potential.</p>



<p><em>On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>



<p><em>On the date of publication, the responsible editor held a LONG position in CRSP.&nbsp;</em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/7-biotech-stocks-to-buy-for-their-game-changing-potential/">7 Biotech Stocks to Buy for Their Game-Changing Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Biotech Stocks to Buy for Their Game-Changing Potential

BofA upgrades Editas to buy, cites reni-cel progress

Truist Financial analyst Joon Lee maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $100.0...

Crispr Therapeutics AG (CRSP) Receives a Buy from Truist Financial

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Crispr Therapeutics: Prepare To Be Bored

ALLO

ALNY

BLUE

DTIL

EDIT

GMED

RGNX

SRPT

VRTX

VYGR

Press Releases

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Health Care

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

CRISPR Therapeutics

CRISPR Therapeutics (CRSP) Forecast

CRISPR Therapeutics (NASDAQ:CRSP) Stock, Quote.Headers.trade-ideas